Impact of abrocitinib on itch, sleep, skin pain and psychological stress in patients with moderate-to-severe atopic dermatitis: pooled analysis from JADE monotherapy trials

被引：0
|
作者：
Bewley, A. [1 ]
Thyssen, J. P. [2 ]
Chiu, W. S. [3 ]
Rojo, R. [4 ]
Biswas, P. [5 ]
Feeney, C. [3 ]
DiBonaventura, M. [5 ]
Misery, L. [6 ]
Stander, S. [7 ]
Cork, M. [8 ]
机构：
[1] Barts Hlth NHS Trust, London, England
[2] Univ Copenhagen, Copenhagen, Denmark
[3] Pfizer Ltd, Tadworth, England
[4] Pfizer Inc, Groton, CT 06340 USA
[5] Pfizer Inc, New York, NY USA
[6] Univ Hosp Ctr Brest, Brest, France
[7] Muenster Univ Hosp, Munster, Germany
[8] Univ Sheffield, Sheffield, S Yorkshire, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2021年 / 185卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
B06
引用
收藏
页码：E72 / E73
页数：2
相关论文
共 50 条
  • [31] Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2
    Yosipovitch, Gil
    Gooderham, Melinda J.
    Staender, Sonja
    Fonacier, Luz
    Szepietowski, Jacek C.
    Deleuran, Mette
    Girolomoni, Giampiero
    Su, John C.
    Bushmakin, Andrew G.
    Cappelleri, Joseph C.
    Feeney, Claire
    Chan, Gary
    Thorpe, Andrew J.
    Valdez, Hernan
    Biswas, Pinaki
    Rojo, Ricardo
    Dibonaventura, Marco
    Myers, Daniela E.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (01) : 127 - 138
  • [32] Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2
    Gil Yosipovitch
    Melinda J. Gooderham
    Sonja Ständer
    Luz Fonacier
    Jacek C. Szepietowski
    Mette Deleuran
    Giampiero Girolomoni
    John C. Su
    Andrew G. Bushmakin
    Joseph C. Cappelleri
    Claire Feeney
    Gary Chan
    Andrew J. Thorpe
    Hernan Valdez
    Pinaki Biswas
    Ricardo Rojo
    Marco DiBonaventura
    Daniela E. Myers
    American Journal of Clinical Dermatology, 2024, 25 : 127 - 138
  • [33] Efficacy and safety of abrocitinib in adolescent patients with moderate-to-severe atopic dermatitis: stratified analysis across three clinical trials
    Simpson, E.
    Lio, P.
    Heath, C.
    Boguniewicz, M.
    Levenberg, M.
    Biswas, P.
    Farooqui, S.
    Kerkmann, U.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E140 - E140
  • [34] Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis
    Yosipovitch, Gil
    de Bruin-Weller, Marjolein
    Wiseman, Marni
    Elberling, Jesper
    Gutermuth, Jan
    Pierce, Evangeline
    Montmayeur, Sonia
    Yang, Fan Emily
    Ding, Yuxin
    Bardolet, Laia
    Chisolm, Sarah
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2025,
  • [35] EFFICACY OF ABROCITINIB AND DUPILUMAB IN PATIENTS WITH ITCH-DOMINANT ATOPIC DERMATITIS: A POOLED ANALYSIS OF 2 RANDOMIZED TRIALS
    Silverberg, Jonathan I.
    Thyssen, Jacob P.
    Lazariciu, Irina
    Valdez, Hernan
    Myers, Daniela E.
    Gueler, Erman
    Chovatiya, Raj
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 31 - 32
  • [36] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase III JADE MONO-2 study
    Silverberg, J.
    Simpson, E. L.
    Thyssen, J. P.
    Gooderham, M.
    Chan, G.
    Feeney, C.
    Biswas, P.
    Valdez, H.
    DiBonaventura, M.
    Nduaka, C.
    Rojo, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E100 - E100
  • [37] Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study
    Eichenfield, Lawrence
    Flohr, Carsten
    Sidbury, Robert
    Szalai, Zsuzsanna
    Galus, Ryszard
    Yao, Zhirong
    Takahashi, Hidetoshi
    Barbarot, S. Ebastien
    Feeney, Claire
    Zhang, Fan
    DiBonaventura, Marco
    Rojo, Ricardo
    Valdez, Hernan
    Chan, Gary
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB146 - AB146
  • [38] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase III, JADE MONO-1 study
    Simpson, E. L.
    Sinclair, R.
    Forman, S.
    Wollenberg, A.
    Asch, R.
    Cork, M.
    Bieber, T.
    Thyssen, J. P.
    Yosipovitch, G.
    Magnolo, N.
    Maari, C.
    Flohr, C.
    Feeney, C.
    Biswas, P.
    Tatulych, S.
    Valdez, H.
    Rojo, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E105 - E106
  • [39] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials
    Gooderham, Melinda J.
    Ardern-Jones, Michael R.
    Guttman-Yassky, Emma
    Ameen, Mahreen
    Simpson, Eric L.
    Chan, Gary
    Biswas, Pinaki
    Chiu, Wing S.
    Watkins, Melissa
    JEADV CLINICAL PRACTICE, 2023, 2 (04): : 753 - 763
  • [40] Patient-reported symptoms and quality of life in Australian patients with moderate-to-severe atopic dermatitis following treatment with abrocitinib: A post hoc analysis of JADE clinical trials
    Tan, Fiona
    Sinclair, Rodney
    Nas, Pablo Fernandez Pe
    Murrell, Dedee
    Foley, Peter
    Freeman, Michael
    Su, John
    Eisman, Samantha
    Rubel, Diana
    Spelman, Lynda
    Surian, Christine
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 28 - 28
12345